Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ENOV Stock Forecast 2026-2027
$26.32
Current Price
$1.51B
Market Cap
Buy 11
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to ENOV Price Targets
+109.0%
To High Target of $55.00
+71.0%
To Median Target of $45.00
+25.4%
To Low Target of $33.00
ENOV Price Momentum
+7.8%
1 Week Change
+16.6%
1 Month Change
-17.6%
1 Year Change
-1.2%
Year-to-Date Change
-30.5%
From 52W High of $37.85
+25.3%
From 52W Low of $21.00
📊 TOP ANALYST CALLS
Did ENOV Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Enovis is one of their latest high-conviction picks.
Latest ENOV Stock Price Targets & Analyst Predictions
Based on our analysis of 19 Wall Street analysts, ENOV has a bullish consensus with a median price target of $45.00 (ranging from $33.00 to $55.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $26.32, the median forecast implies a 71.0% upside. This outlook is supported by 11 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from David Turkaly at JMP Securities, projecting a 109.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ENOV Analyst Ratings
11
Buy
1
Hold
0
Sell
ENOV Price Target Range
Low
$33.00
Average
$45.00
High
$55.00
Current: $26.32
Latest ENOV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ENOV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 6, 2026 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $35.00 |
| Feb 26, 2026 | Needham | Mike Matson | Buy | Maintains | $52.00 |
| Feb 26, 2026 | BTIG | Ryan Zimmerman | Buy | Maintains | $43.00 |
| Jan 6, 2026 | BTIG | Ryan Zimmerman | Buy | Initiates | $41.00 |
| Dec 17, 2025 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $50.00 |
| Dec 17, 2025 | Freedom Capital Markets | Keith Hinton | Buy | Initiates | $45.00 |
| Nov 7, 2025 | Wells Fargo | Vik Chopra | Overweight | Maintains | $42.00 |
| Aug 8, 2025 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $58.00 |
| Aug 8, 2025 | Wells Fargo | Vik Chopra | Overweight | Maintains | $41.00 |
| Aug 8, 2025 | UBS | Danielle Antalffy | Buy | Maintains | $57.00 |
| Aug 7, 2025 | Needham | Mike Matson | Buy | Maintains | $49.00 |
| Jul 8, 2025 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $46.00 |
| May 14, 2025 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $70.00 |
| May 9, 2025 | Needham | Mike Matson | Buy | Maintains | $57.00 |
| May 9, 2025 | JMP Securities | David Turkaly | Market Outperform | Maintains | $55.00 |
| Apr 9, 2025 | Needham | Mike Matson | Buy | Reiterates | $64.00 |
| Apr 2, 2025 | Needham | Mike Matson | Buy | Reiterates | $64.00 |
| Feb 27, 2025 | Needham | Mike Matson | Buy | Maintains | $64.00 |
| Nov 7, 2024 | Needham | Mike Matson | Buy | Reiterates | $65.00 |
| Oct 3, 2024 | JMP Securities | David Turkaly | Market Outperform | Initiates | $62.00 |
Enovis Corporation (ENOV) Competitors
The following stocks are similar to Enovis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Enovis Corporation (ENOV) Financial Data
Enovis Corporation has a market capitalization of $1.51B with a P/E ratio of -1.3x. The company generates $2.25B in trailing twelve-month revenue with a -52.7% profit margin.
Revenue growth is +2.6% quarter-over-quarter, while maintaining an operating margin of +6.1% and return on equity of -58.3%.
Valuation Metrics
Market Cap
$1.51B
Enterprise Value
$2.79B
P/E Ratio
-1.3x
PEG Ratio
0.1x
Price/Sales
0.6x
Growth & Margins
Revenue Growth (YoY)
+2.6%
Gross Margin
+60.7%
Operating Margin
+6.1%
Net Margin
-52.7%
EPS Growth
+2.6%
Financial Health
Cash/Price Ratio
+2.4%
Current Ratio
2.0x
Debt/Equity
92.5x
ROE
-58.3%
ROA
+1.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Enovis Corporation (ENOV) Business Model
About Enovis Corporation
What They Do
Develops innovative medical technology solutions.
Business Model
Enovis Corporation generates revenue by providing a broad range of healthcare equipment, including advanced surgical solutions, rehabilitation devices, and other medical innovations to healthcare providers and patients. Their products are targeted at various medical specialties like orthopedics, pain management, and wound care, enhancing surgical efficiencies and improving patient recovery.
Additional Information
With a strong emphasis on research and development, Enovis Corporation aims to advance medical science and enhance patient-centric care. The company plays a crucial role in supporting hospitals, clinics, and healthcare professionals, positioning itself as a significant player in the evolving healthcare market.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
7,802
CEO
Mr. Damien McDonald
Country
United States
IPO Year
2022
Website
www.enovis.comEnovis Corporation (ENOV) Latest News & Analysis
Latest News
Analyst Backs Enovis On Cash Flow Turnaround
2 days ago
Quick Summary
The firm noted that despite the stock's underperformance in the past two years, improved cash flow execution could lead to multiple expansion opportunities.
Why It Matters
Execution on cash flow can lead to improved financial performance and potentially higher stock valuations, indicating a positive outlook for future investment returns.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
Enovis Corporation (NYSE: ENOV) will host an investor conference call on May 7, 2026, at 8:30 a.m. ET to discuss Q1 2026 financial results, with a press release issued earlier that day.
Why It Matters
Enovis' upcoming earnings call may reveal key financial performance indicators, impacting stock valuation and investor sentiment in the medical technology sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Wall Street Analysts See a 100.71% Upside in Enovis (ENOV): Can the Stock Really Move This High?
26 days ago
Quick Summary
Enovis (ENOV) has a consensus price target indicating a 100.7% upside potential. Upward earnings estimate revisions suggest potential near-term stock gains.
Why It Matters
The 100.7% upside potential for Enovis (ENOV) suggests significant growth opportunity, while positive earnings revisions indicate possible near-term stock appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Royce Small-Cap Fund FY 2025: What Worked
1 month ago
Quick Summary
In 2025, five equity sectors, notably Industrials, Financials, and IT, boosted Fund performance. Alamos Gold's stock rose due to a favorable earnings outlook and stock buybacks, with Q1 revenue up 48% YoY.
Why It Matters
Positive performance in key sectors and strong earnings growth at Alamos Gold indicate potential for continued investment returns, signaling robust market conditions and investor confidence.
Source: Seeking Alpha
Market Sentiment:
Positive
Wall Street Analysts Think Enovis (ENOV) Could Surge 76.62%: Read This Before Placing a Bet
1 month ago
Quick Summary
Analysts' price targets for Enovis (ENOV) suggest a potential 76.6% upside, supported by a consensus increase in earnings estimates.
Why It Matters
Analysts' targets suggest a significant upside for Enovis (ENOV) stock, indicating potential growth. Increased earnings estimates reflect positive sentiment, which may attract investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Front Street acquired 156,069 shares of Enovis in Q4, increasing the position's value by $3.4 million due to trading activity and price changes.
Why It Matters
Front Street's increased investment in Enovis signals confidence in the company's growth, potentially influencing market sentiment and stock performance, which could affect investor decisions.
Source: The Motley Fool
Market Sentiment:
Positive
Frequently Asked Questions About ENOV Stock
What is Enovis Corporation's (ENOV) stock forecast for 2026?
Based on our analysis of 19 Wall Street analysts, Enovis Corporation (ENOV) has a median price target of $45.00. The highest price target is $55.00 and the lowest is $33.00.
Is ENOV stock a good investment in 2026?
According to current analyst ratings, ENOV has 11 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $26.32. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ENOV stock?
Wall Street analysts predict ENOV stock could reach $45.00 in the next 12 months. This represents a 71.0% increase from the current price of $26.32. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Enovis Corporation's business model?
Enovis Corporation generates revenue by providing a broad range of healthcare equipment, including advanced surgical solutions, rehabilitation devices, and other medical innovations to healthcare providers and patients. Their products are targeted at various medical specialties like orthopedics, pain management, and wound care, enhancing surgical efficiencies and improving patient recovery.
What is the highest forecasted price for ENOV Enovis Corporation?
The highest price target for ENOV is $55.00 from David Turkaly at JMP Securities, which represents a 109.0% increase from the current price of $26.32.
What is the lowest forecasted price for ENOV Enovis Corporation?
The lowest price target for ENOV is $33.00 from at , which represents a 25.4% increase from the current price of $26.32.
What is the overall ENOV consensus from analysts for Enovis Corporation?
The overall analyst consensus for ENOV is bullish. Out of 19 Wall Street analysts, 11 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $45.00.
How accurate are ENOV stock price projections?
Stock price projections, including those for Enovis Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 4:04 PM UTC